Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Kai Duan, Bende Liu, Cesheng Li, Huajun Zhang, Ting Yu, Jieming Qu, Min Zhou, Li Chen, Shengli Meng, Yong Hu, Cheng Peng, Mingchao Yuan, Jinyan Huang, Zejun Wang, Jianhong Yu, Xiaoxiao Gao, Dan Wang, Xiaoqi Yu, Li Li, Jiayou Zhang, Xiao Wu, Bei Li, Yanping Xu, Wei Chen, Yan Peng, Yeqin Hu, Lianzhen Lin, Xuefei Liu, Shihe Huang, Zhijun Zhou, Lianghao Zhang, Yue Wang, Zhi Zhang, Kun Deng, Zhiwu Xia, Qin Gong, Wei Zhang, Xiaobei Zheng, Ying Liu, Huichuan Yang, Dongbo Zhou, Ding Yu, Jifeng Hou, Zhengli Shi, Saijuan Chen, Zhu Chen, Xinxin Zhang, Xiaoming Yang, Kai Duan, Bende Liu, Cesheng Li, Huajun Zhang, Ting Yu, Jieming Qu, Min Zhou, Li Chen, Shengli Meng, Yong Hu, Cheng Peng, Mingchao Yuan, Jinyan Huang, Zejun Wang, Jianhong Yu, Xiaoxiao Gao, Dan Wang, Xiaoqi Yu, Li Li, Jiayou Zhang, Xiao Wu, Bei Li, Yanping Xu, Wei Chen, Yan Peng, Yeqin Hu, Lianzhen Lin, Xuefei Liu, Shihe Huang, Zhijun Zhou, Lianghao Zhang, Yue Wang, Zhi Zhang, Kun Deng, Zhiwu Xia, Qin Gong, Wei Zhang, Xiaobei Zheng, Ying Liu, Huichuan Yang, Dongbo Zhou, Ding Yu, Jifeng Hou, Zhengli Shi, Saijuan Chen, Zhu Chen, Xinxin Zhang, Xiaoming Yang

Abstract

Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 × 109/L vs. 0.76 × 109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesions within 7 d. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.

Keywords: COVID-19; convalescent plasma; pilot project; treatment outcome.

Conflict of interest statement

The authors declare no competing interest.

Copyright © 2020 the Author(s). Published by PNAS.

Figures

Fig. 1.
Fig. 1.
Chest CTs of two patients. (A) Chest CT of patient 9 obtained on February 9 (7 dpoi) before CP transfusion (10 dpoi) showed ground-glass opacity with uneven density involving the multilobal segments of both lungs. The heart shadow outline was not clear. The lesion was close to the pleura. (B) CT Image of patient 9 taken on February 15 (13 dpoi) showed the absorption of bilateral ground-glass opacity after CP transfusion. (C) Chest CT of patient 10 was obtained on February 8 (19 dpoi) before CP transfusion (20 dpoi). The brightness of both lungs was diffusely decreased, and multiple shadows of high density in both lungs were observed. (D) Chest CT of patient 10 on February 18 (29 dpoi) showed those lesions improved after CP transfusion.
Fig. 2.
Fig. 2.
Dynamic changes of laboratory parameters in all patients. The dotted horizontal line represents the reference value range. SaO2, oxyhemoglobin saturation; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Lym, lymphocyte.
Fig. 3.
Fig. 3.
Change of laboratory parameters in patient 1. The x axis represents the day post-CP transfusion. The dotted horizontal line represents the reference value range.

References

    1. Zhou P., et al. , A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
    1. Chen N., et al. , Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 395, 507–513 (2020).
    1. World Health Organization , Coronavirus disease (COVID-19) Pandemic. . Accessed 11 March 2020.
    1. Lu H., Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. Trends 14, 69–71 (2020).
    1. Wang M., et al. , Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020).
    1. Holshue M. L., et al. ; Washington State 2019-nCoV Case Investigation Team , First case of 2019 novel coronavirus in the United States. N. Engl. J. Med. 382, 929–936 (2020).
    1. Russell C. D., Millar J. E., Baillie J. K., Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395, 473–475 (2020).
    1. Shang L., Zhao J., Hu Y., Du R., Cao B., On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 395, 683–684 (2020).
    1. Cheng Y., et al. , Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24, 44–46 (2005).
    1. Zhou B., Zhong N., Guan Y., Treatment with convalescent plasma for influenza A (H5N1) infection. N. Engl. J. Med. 357, 1450–1451 (2007).
    1. Hung I. F., et al. , Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 52, 447–456 (2011).
    1. Ko J. H., et al. , Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience. Antivir. Ther. 23, 617–622 (2018).
    1. Mair-Jenkins J., et al. ; Convalescent Plasma Study Group , The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J. Infect. Dis. 211, 80–90 (2015).
    1. van Griensven J., et al. ; Ebola-Tx Consortium , Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 374, 33–42 (2016).
    1. Lee P. I., Hsueh P. R., Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J. Microbiol. Immunol. Infect., in press.
    1. Chen L., Xiong J., Bao L., Shi Y., Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 20, 398–400 (2020).
    1. Channappanavar R., Perlman S., Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39, 529–539 (2017).
    1. Huang C., et al. , Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
    1. Marano G., et al. , Convalescent plasma: New evidence for an old therapeutic tool? Blood Transfus. 14, 152–157 (2016).
    1. Wong V. W., Dai D., Wu A. K., Sung J. J., Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med. J. 9, 199–201 (2003).
    1. Yeh K. M., et al. , Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J. Antimicrob. Chemother. 56, 919–922 (2005).
    1. Kong L. K., Zhou B. P., Successful treatment of avian influenza with convalescent plasma. Hong Kong Med. J. 12, 489 (2006).
    1. Cao W. C., Liu W., Zhang P. H., Zhang F., Richardus J. H., Disappearance of antibodies to SARS-associated coronavirus after recovery. N. Engl. J. Med. 357, 1162–1163 (2007).
    1. Arabi Y. M., et al. , Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg. Infect. Dis. 22, 1554–1561 (2016).
    1. Eickmann M., et al. , Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively. Transfusion 58, 2202–2207 (2018).
    1. Mora-Rillo M., et al. ; La Paz-Carlos III University Hospital Isolation Unit , Acute respiratory distress syndrome after convalescent plasma use: Treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir. Med. 3, 554–562 (2015).
    1. Benson A. B., Moss M., Silliman C. C., Transfusion-related acute lung injury (TRALI): A clinical review with emphasis on the critically ill. Br. J. Haematol. 147, 431–443 (2009).
    1. Halstead S. B., Dengue antibody-dependent enhancement: Knowns and unknowns. Microbiol. Spectr. 2, AID-0022-2014 (2014).
    1. Wang S. F., et al. , Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem. Biophys. Res. Commun. 451, 208–214 (2014).
    1. World Health Organization , Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim guidance. . Accessed 13 March 2020.
    1. National Health Commission of China , Guideline for diagnosis and treatment for novel coronavirus pneumonia (fifth edition). . Accessed 4 February 2020.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다